Precision Epigenomics Inc. Press Releases - EIN Presswire

Published on November 18, 2025 - 15:14 GMT

New Clinical Test Developed to Accurately Classify Pleural Effusions

Precision Epigenomics presents EPISEEK®-MPE clinical data at Association for Molecular Pathology (AMP) TUCSON, AZ, UNITED STATES, November 18, 2025 /⁨EINPresswire.com⁩/ -- Precision Epigenomics, a molecular diagnostics company developing next-generation …

Distribution channels: Conferences & Trade Fairs, Healthcare & Pharmaceuticals Industry ...

Published on October 9, 2025 - 18:56 GMT

Precision Epigenomics Named 'Startup of the Year' by University of Arizona

Honored for Pioneering Early Cancer Detection Technology TUCSON, AZ, UNITED STATES, October 9, 2025 /⁨EINPresswire.com⁩/ -- Precision Epigenomics, a molecular diagnostics innovator transforming cancer care, proudly announced today that it has been honored …

Distribution channels: Healthcare & Pharmaceuticals Industry, Science ...

Published on October 3, 2025 - 19:35 GMT

EPISEEK Detects Stages I-IV Pancreatic Cancer with Minimal Sample Volume

Precision Epigenomics presents the latest EPISEEK Multi-Cancer Early Detection (MCED) test performance data at AACR Conference this week. TUCSON, AZ, UNITED STATES, October 3, 2025 /⁨EINPresswire.com⁩/ -- Precision Epigenomics® is pleased to present …

Distribution channels: Beauty & Hair Care, Healthcare & Pharmaceuticals Industry ...

Published on August 1, 2025 - 15:30 GMT

Precision Epigenomics Announces Nannon Roosa, PMP, CPA, FACMPE, as Vice President, Technology Licensing Strategy

Roosa joins the team to strengthen strategic initiatives surrounding laboratory licensing of the EPISEEK multicancer early detection tests and other products. TUCSON, AZ, UNITED STATES, August 1, 2025 /⁨EINPresswire.com⁩/ -- Precision Epigenomics is …

Distribution channels: Healthcare & Pharmaceuticals Industry, World & Regional ...

Published on June 2, 2025 - 15:00 GMT

Precision Epigenomics Presents Validation of EPISEEK™, a Multi-Cancer Early Detection Test, at 2025 ASCO Annual Meeting

The data support the EPISEEK™ test’s potential as an accurate and cost-effective solution for multi-cancer early detection through a simple blood draw. PHOENIX, AZ, UNITED STATES, June 2, 2025 /⁨EINPresswire.com⁩/ -- Precision Epigenomics, a biotechnology …

Distribution channels: Healthcare & Pharmaceuticals Industry ...

Published on November 22, 2024 - 02:00 GMT

Precision Epigenomics Shares Abstracts Showing Performance of Assays for Melanoma and Brain Cancer Detection

Precision Epigenomics announced that the company presented data supporting the critical role of its melanoma classifier. TUCSON, AZ, UNITED STATES, November 21, 2024 /⁨EINPresswire.com⁩/ -- Precision Epigenomics, the developer of the EPISEEK™ multi-cancer …

Distribution channels: Business & Economy, Culture, Society & Lifestyle ...

Published on September 11, 2024 - 09:34 GMT

Precision Epigenomics Announces Closing of $1.5M Series A1 Funding

With this funding, Precision Epigenomics has raised more than $3.9M in investments helping move the company into the revenue stage. TUCSON, AZ, UNITED STATES, September 11, 2024 /⁨EINPresswire.com⁩/ -- Precision Epigenomics Inc. announces the completion …

Distribution channels: Culture, Society & Lifestyle, Healthcare & Pharmaceuticals Industry ...